New drug combo targets Hard-to-Treat leukemia
NCT ID NCT04150887
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-phase study tests a new drug called cusatuzumab, given alongside usual treatments, for adults with acute myeloid leukemia (AML) who cannot have strong chemotherapy. The main goal is to check the safety and side effects of this combination. About 61 participants will receive the drug to see if it is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
City of Hope
Duarte, California, 91010, United States
-
INSELSPITAL, Universitätsspital Bern
Bern, 3010, Switzerland
-
Instytut Hematologii i Transfuzjologii
Warsaw, 02-776, Poland
-
Kantonsspital St.Gallen
Sankt Gallen, 9007, Switzerland
-
Klinikum der Universitaet Muenchen
München, 81377, Germany
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14203, United States
-
Szpital Uniwersytecki w Krakowie
Krakow, 31-501, Poland
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
Universitaetsklinik Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Universitaetsklinikum Leipzig
Leipzig, 04103, Germany
-
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7, Canada
-
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, 15232, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
University of Toronto
Toronto, Ontario, M5G 2M9, Canada
-
University of Vermont
Burlington, Vermont, 05401, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
-
Wisconsin Medical Center
Milwaukee, Wisconsin, 53226, United States
-
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
Lodz, 93-513, Poland
Conditions
Explore the condition pages connected to this study.